Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BPhytohealth Corp. 〉PHN031 (Osteoporosis prevention)

PHN031 (Osteoporosis prevention)

PHN031 (Osteoporosis prevention)

The PHN031 project has been completed US FDA Phase IIa clinical trials for the prevention of osteoporosis and was chosen to be the Cross-Strait Drug Co-Development Project.The CFDA's gGuidelines-compliant CMC are uunderprepared

Request for Collaboration
Overview
Advantages of the product
  • Selection of native plants for control the medicinal origin and quality
  • Long-term human experience show no drug- related toxicity
  • There are dual affects in enhancing bone formation index and restraining bone loss index
  • Characteristic fingerprint to ensure superior quality control
  • Well-defined specifications to prove the consistency of quality among batches
Application
Prevention of osteoporosis in menopausal women
Patent Portfolio
The patent application is under reviewed in US, Korea, Canada, China, European Union.
Collaboration Options
  • Licensing
  • Co-development
People who like this also like
  • ELISA (FMD NSP Ab test)ELISA (FMD NSP Ab test)
  • Zwitterionic interface processing technologyZwitterionic interface processing technology
  • Candidate selectionCandidate selection
  • Six Genomic Technology PlatformsSix Genomic Technology Platforms
  • Advanced technology in material scienceAdvanced technology in material science
  • PHN015 (Hemorrhage stroke)PHN015 (Hemorrhage stroke)
  • RD statusRD status
  • SB05SB05
  • TLC178TLC178
  • Quantitative analysis of SMN1 and SMN2 genes based on DHPLCQuantitative analysis of SMN1 and SMN2 genes based on DHPLC